

Regulations and other acts

Gouvernement du Québec

O.C. 667-2007, 14 August 2007

An Act respecting the Ministère des Affaires municipales et des Régions (R.S.Q., c. M-22.1)

Appointment of four additional members to the board of directors of the Conférence régionale des élus de Lanaudière

WHEREAS, under the ninth paragraph of section 21.8 of the Act respecting the Ministère des Affaires municipales et des Régions (R.S.Q., c. M-22.1), the Government may, by order, on the request of a regional conference of elected officers, allow the regional conference to appoint to its board of directors one or more additional representatives of a local municipality, chosen by the council of the local municipality from among its members;

WHEREAS the Conférence régionale des élus de Lanaudière requests that an additional representative of Ville de Mascouche and an additional representative of Ville de Terrebonne be appointed to sit on its board of directors;

WHEREAS, under the tenth paragraph of that section 21.8, the Government may, by order, on the request of a regional conference of elected officers, amend Schedule B to the Act to add one or more rural local municipalities so that such a municipality is represented by its mayor on the board of directors of the conference;

WHEREAS the Conférence régionale des élus de Lanaudière requests that Schedule B to the Act respecting the Ministère des Affaires municipales et des Régions be amended by adding Municipalité de L'Épiphanie and Municipalité de Saint-Donat;

WHEREAS it is advisable to give effect to those requests;

IT IS ORDERED, therefore, on the recommendation of the Minister of Municipal Affairs and Regions:

THAT Ville de Mascouche and Ville de Terrebonne each designate an additional representative to sit on the board of directors of the Conférence régionale des élus de Lanaudière;

THAT Schedule B to the Act respecting the Ministère des Affaires municipales et des Régions (R.S.Q., c. M-22.1) be amended by inserting “Municipalité de L'Épiphanie” after “Ville d'East Angus” and “Municipalité de Saint-Donat” after “Ville de Saint-Cézaire”.

GÉRARD BIBEAU,
Clerk of the Conseil exécutif

8277

Gouvernement du Québec

O.C. 668-2007, 14 August 2007

Medical Act
(R.S.Q., c. M-9)

Professional Code
(R.S.Q., c. C-26)

Physicians

— **Activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians**

— **Amendments**

Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians

WHEREAS, under subparagraph *b* of the first paragraph of section 19 of the Medical Act (R.S.Q., c. M-9), the Bureau of the Collège des médecins du Québec shall by regulation determine among the activities referred to in the second paragraph of section 31 of that Act those which, under certain prescribed conditions, may be engaged in by classes of persons other than physicians;

WHEREAS, in accordance with section 94.1 of the Professional Code (R.S.Q., c. C-26), the Bureau of a professional order may, in a regulation that it is authorized to make under the Code or under an Act constituting the professional order, make compulsory a standard established by a government or body and provide that reference to such a standard includes any subsequent amendment made to it;

WHEREAS, under section 95 of the Professional Code and subject to sections 95.1 and 95.2 of the Code, every regulation made by the Bureau of a professional order under the Code or an Act constituting a professional order shall be transmitted to the Office des professions du Québec for examination and submitted, with the recommendation of the Office, to the Government which may approve it with or without amendment;

WHEREAS, in accordance with that provision, the Government approved, by Order in Council 996-2005 dated 26 October 2005, the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians;

WHEREAS, under section 36.1 of the Nurses Act (R.S.Q., c. I-8), nurses may, if they are so authorized by regulations under paragraph *f* of section 14 of the Nurses Act and subparagraph *b* of the first paragraph of section 19 of the Medical Act, engage in one or more of the following activities referred to in the second paragraph of section 31 of the Medical Act:

- (1) prescribing diagnostic examinations;
- (2) using diagnostic techniques that are invasive or entail risks of injury;
- (3) prescribing medications and other substances;
- (4) prescribing medical treatment; and
- (5) using techniques or applying medical treatments that are invasive or entail risks of injury;

WHEREAS it is expedient to amend the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians to allow nurses to engage in the activities referred to in the second paragraph of section 31 of the Medical Act;

WHEREAS, in accordance with the second paragraph of section 19 of the Medical Act, the Office de professions du Québec and the Ordre des infirmières et des infirmiers du Québec were consulted before the making of the Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians;

WHEREAS the Bureau of the College made the Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians;

WHEREAS, in accordance with sections 10 and 11 of the Regulations Act (R.S.Q., c. R-18.1), a draft of the Regulation was published in Part 2 of the *Gazette officielle du Québec* of 7 February 2007 with a notice that it could be submitted to the Government for approval on the expiry of 45 days following that publication;

WHEREAS, in accordance with section 95 of the Professional Code, the Office has examined the Regulation and made its recommendation;

WHEREAS it is expedient to approve the Regulation with amendments;

IT IS ORDERED, therefore, on the recommendation of the Minister responsible for the administration of legislation respecting the professions:

THAT the Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians, attached to this Order in Council, be approved.

GÉRARD BIBEAU,
Clerk of the Conseil exécutif

Regulation amending the Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians*

Medical Act
(R.S.Q., c M.-9, s. 19, 1st par., subpar *b*)

Professional Code
(R.S.Q., c. C-26, s. 94.1)

1. The Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians is amended by replacing in subparagraph (1) of the second paragraph of the Section 2 of the French version, the words “elle a” by the word “avoir”.

* The Regulation respecting the activities contemplated in section 31 of the Medical Act which may be engaged in by classes of persons other than physicians was approved by Order in Council 996-2005 of October 26, 2005 (2005), 137 *G.O.* 2, 4813. The regulation has not been amended since then.

2. Section 6 of this Regulation is amended by inserting:

(1) in subparagraph (1) of the French version, after the words “au sens de” of the word “la”;

(2) in subparagraph (2) after the word “provisions” of the words “of Division II”;

3. Section 7 of this Regulation is amended by inserting:

(1) in subparagraph (1) of the French version, after the words “au sens de” of the word “la”;

(2) in subparagraph (2) after the word “provisions” of the words “of Division III”;

4. Section 8 of this Regulation is amended by inserting:

(1) in subparagraph (1) of the French version, after the words “au sens de” of the word “la”;

(2) in subparagraph (2) after the word “with” of the words “the provisions of Division II”.

5. This Regulation is amended by inserting after section 8 the following subdivision:**“§2.1 Terms and conditions for authorization of primary care**

8.1 A specialized nurse practitioner in primary care is authorized to engage in an activity stipulated in section 5, in primary care, under the following terms and conditions:

(1) he or she engages in that activity with an ambulatory clientele:

(a) requiring the evaluation of the person’s health or detection of a health problem;

(b) presenting a common health problem;

(c) presenting a stable chronic disease;

(d) requiring the follow-up of a pregnancy.

(2) he or she engages in that activity in partnership with a family physician;

When the nurse practises elsewhere than in a centre operated by an establishment in the meaning of the Law respecting health services and social services or the Law respecting health services and social services for Cree and Inuit Native persons, the partnership must be recognized in a written agreement.

8.2 For the purposes of this Division, the term “common health problem” means a health problem that presents the following characteristics:

(1) a relatively high incidence in the community;

(2) clinical symptoms and signs usually affecting a single system;

(3) an absence of deterioration in the general condition of the person;

(4) usually a quick and favorable course;

8.3 For the purposes of this Division, “stable chronic disease” means a disease that has been the subject of a diagnosis by a physician and of a medical treatment plan giving the expected results;

8.4 The specialized nurse practitioner in primary care engages in his or her activities under the following terms and conditions:

(1) he or she prescribes diagnostic examinations stipulated with Schedule I of this Regulation;

(2) he or she uses the following diagnostic techniques:

(a) pelvic examination

(b) rectal touch

(c) cervico-vaginal smear

(d) radial arterial puncture

(3) he or she prescribes medications and other substances in accordance with Schedule II of this Regulation and the provisions of Division II of the Règlement sur les normes relatives aux ordonnances faites par un médecin, adapted as required;

(4) he or she prescribes the following medical treatments:

(a) cryotherapy, except on the face and internal genital organs;

(b) eye irrigation;

(c) fluorescein staining;

(d) irrigating ears;

(e) oxygenotherapy;

(f) peripheral venous access;

(g) cleansing enema;

(h) bladder catheterization;

(i) nasogastric tube

(1) he or she uses the following medical techniques or applies the following medical treatments:

(a) suture a wound, except below the fascia or in the presence of underlying lesions;

(b) incise and drain an abscess above the fascia;

(c) install a esophageal tracheal double cannula airway device.

8.5 The specialized nurse practitioner in primary care must request the intervention of the partner physician in the following cases:

(1) his or her evaluation does not allow the clear identification of the common health problem, the criteria to initiate the medical treatment are not clear or the situation exceeds the skills of the specialized nurse practitioner in primary care, specifically in the presence of one of the following factors:

(a) a persistent or recurrent sign or symptom to which no cause can be assigned;

(b) a sign, a symptom or a result of medical imaging or laboratory analysis suggesting the presence of an undiagnosed chronic or systemic disease;

(c) a symptom or an analysis result demonstrating the decline or alteration of the function of an organ or a system;

(d) a symptom, a sign or a laboratory analysis result suggesting a recurrent or persistent infection;

(e) an atypical manifestation of a common disease or an unusual reaction to treatment;

(f) a sign or a symptom of change of behavior which cannot be attributed to a specific cause.

(2) he or she notes that the growth or development of a newborn, an infant or a child is abnormal or observes the presence of a sign or a symptom of disease in the newborn or the infant of three months old or less other than thrush, seborrheic dermatitis, diaper rash or tear duct obstruction;

(3) there is a suspicion of abuse or the presence of a sign of abuse or a symptom of a sexually transmitted infection in a child;

(4) a chronic condition becomes worse, especially in the presence of one of the following factors:

(a) a symptom or a result of laboratory analysis indicating deterioration of a patient;

(b) the unexpected deterioration of the condition of a patient already treated for a diagnosed disease.

(5) a woman more than 32 weeks pregnant;

(6) his or her evaluation allows the identification of a symptom, a sign or a result of medical imaging or laboratory analysis suggesting a risk for the pregnant woman or the unborn child.

(7) the situation imperils the life or the physical or mental integrity of a person.

Further to the intervention of the partner physician, he or she may continue the practice of the activities stipulated in section 8.4 within the limits of the medical treatment plan determined by this physician.”

6. Section 9 of this Regulation is amended by:

(1) replacing in the second subparagraph the words “in subdivision 2” by the words “in subdivisions 2 and 3”;

(2) inserting in paragraph (1) of the second subparagraph, after the word “specialist” the words “of the specialty contemplated or of a family physician as appropriate,”.

7. Section 10 of this Regulation is amended by:

(1) replacing in the second subparagraph the words “in subdivision 2” by the words “in subdivisions 2 and 3”;

(2) inserting in paragraph (1) of the second subparagraph, after the word “specialist”, the words “of the specialty contemplated or of a family physician as appropriate,”.

8. This Regulation is amended by adding, at the end, the following Schedules:

“SCHEDULE I

(s. 8.4, par. (1))

1. RADIOLOGICAL EXAMINATIONS

(1) head and neck

- mandibula
- nasal bone

(2) chest

- lungs
- thorax (rib cage)

(3) spine

- cervical spine
- dorsal spine
- lumbosacral spine

(4) upper limbs

- scapula
- shoulder
- clavicle
- humerus
- elbow
- forearm
- wrist
- hand
- fingers

(5) lower limbs

- hip
- femur
- knee and patella
- leg
- ankle
- foot
- toes

(6) abdomen

- abdomen

(7) miscellaneous

- mammography
- osteodensitometry

2. ULTRASOUND EXAMINATIONS

(1) breast (thorax)

- breast ultrasonography as part of an abnormal screening mammogram

(2) abdomen

- abdominal ultrasound
- pelvic ultrasound

(3) obstetrics

- obstetrical ultrasound

(4) genital organs

- ultrasound of scrotum

(5) surface ultrasound

- peripheral venous system

3. OTHER DIAGNOSTIC TESTS

- Resting electrocardiogram
- Pulmonary function tests (spirometry, peak expiratory flow, FEV1)
- Ambulatory monitoring of blood pressure (ABPM)

4. LABORATORY ANALYSES

(1) microbiology*(a)* fresh vaginal state*(b)* cultures

- expectorations
- throat
- urine
- cervical
- urethral
- stools
- purulent discharge
- fungus

(c) specimens for viral testing

- flu
- herpes simplex
- rotavirus
- respiratory syncytial virus

(d) testing

- for *C. Difficile*
- for BK in expectoration (tuberculosis)
- for pinworms
- for parasites in stools

(e) serology

- hepatitis A, B, C antigens or antibodies
- Elisa syphilis test
- non-syphilis test: VDRL
- HIV antibody
- herpes and chlamydia by immunofluorescence method
- C-reactive protein excluding ultrasensitive
- mono test

(2) biochemistry/blood

- amylase
- bilirubin, direct and total
- chlorides
- creatine phosphor-kinase (CPK)
- creatinine
- assays of phenobarbital, lithium, carbamazepine, theophylline, digoxin, dilantin, valproic acid
- hormonal assays:
 - follicle-stimulating hormone (FSH)
 - luteinizing hormone (LH)
 - thyreotropic hormone (TSH)
- vitamin assays:
 - vitamin B12
 - folic acid
- gamma glutamyl transferase (GGT)
- glycaemia
- orally provoked hyperglycemia
- glycated aemoglobin HbA1c
- iron binding capacity
- iron, ferritin
- lactose tolerance test
- presence of lead in the blood
- lipase
- lipid check-up
- arterial and capillary gas
- alkaline phosphatase
- phosphorous
- electrolytes
- total protein
- prealbumin and albumin
- transaminase
- uric acid
- sweat test
- street and date-rape drugs and blood alcohol level testing
- occult blood in stools
- β hCG (qualitative)

(3) biochemistry/urine

- urinalysis
- microalbuminuria on urination or 24-hour urine collection
- pregnancy test
- 24-hour creatinine clearance
- street and date-rape drugs

• enzyme technique testing:

- chlamydia
- gonorrhoea

(4) cytology

- cervico-vaginal smear
- spermogram
- test for sperm, post-vasectomy or in vaginal fluid

(5) hematology

- haemogram
- coagulogram
- prothrombin time (PT – RNI)
- activated partial thrombin time (PPT or APPT)
- reticulocytes count
- sedimentation rate
- blood group determination (crossmatch test)

(6) antenatal screening

- anticytomegalovirus antibody
- toxoplasmosis antibody
- B-19 parvovirus
- rubeola antibody
- anti-varicella antibody
- alpha-fetoprotein, estradiol

SCHEDULE II

(s. 8.4, subpar. (3))

LIST OF CLASSES OF MEDICATION THAT THE NURSE PRACTITIONER SPECIALIZED IN PRIMARY CARE CAN PRESCRIBE WITH OR WITHOUT RESTRICTION

This list is based in the classification used by the Régie de l'assurance maladie du Québec to establish the list of medications.

Specifications

P	Can be prescribed, renewed or stopped unless there is a limit indicated.
R	Can be prescribed according to the original dose to maintain treatment, provided that the medication in question has already been prescribed for the patient by the partner physician (renewal). Maximum duration of six months.
A	Can be prescribed as dose adjustment provided that the drug in question had been prescribed for the patient by the partner physician and the physician has established a medical treatment plan (as part of joint follow-up).

Specifications		
4: 00	Antihistamine Drugs	P
8: 00	Anti-infective Agents	
8: 08	Mebendazole	P (orally only)
8: 12.04	Nystatin	P (orally only)
8: 12.06	Cephalosporins	P (orally only)
8: 12.12	Macrolides	P (orally only)
8: 12.16	Penicillins	P (orally only)
8: 12.18	Ciprofloxacin	P (5 days or less) (orally only)
	Norfloxacin	P (5 days or less) (orally only)
8: 12.20	Sulfonamides	P (orally only)
	Trimethoprim / Sulfamethoxazole	R (orally only)
8: 12.24	Tetracyclines	P (orally only)
8: 12.28	Antibacterials, Miscellaneous	(orally only)
	Clindamycin	P (pediatrics only)
	Erythromycine/ Acetylsulfisoxazol	P
8: 14.08	Fluconazol (single dose)	P (orally only)
8: 16.04	Antituberculosis Agents	R (orally only)
8: 18.04	Adamantanes	P (7 days or less) (orally only)
8: 18.32	Nucleosides and Nucleotides	P (7 days or less) (orally only)
8: 30.08	Antimalarials	P (for prevention) (orally only)
8: 30.92	Metronidazol	P (orally only)
8: 36	Urinary anti-infectives	P (orally only)
10: 00	Antineoplastic Agents	
	Methotrexate as Antirhumatismal Agent	R
	Tamoxifen	R

Specifications		
12: 00	Autonomic Drugs	
12: 08.04	Antiparkinsonian Agents	R
12: 08.08	Ipratropium (Bromide)	R (aerosol)
12: 12.08	Beta-Adrenergic Agonists	
	Formoterol	R (14 days or less for 1 treatment) or R
	Salbutamol (sulfate)	P
	Salmeterol	R
	Terbutaline	R
12: 12.12	Alpha and beta- Adrenergic Agonists	
	Epinephrin (chlorhydrate)	P (in an emergency)
	Epinephrin	R (auto-injector)
12: 16	Sympatholytic Agents	R
12: 92	Nicotine	P
20: 00	Blood Formation, Coagulation and Thrombosis	
20: 04.04	Iron Preparations	P (for 1 month) – orally only
20: 12.04	Anticoagulants	R and A – orally only
24: 00	Cardiovascular Drugs	
24: 04.08	Cardiotonic Agents	R
24: 06.04	Bile Acid Sequestrants	R
24: 06.06	Fibric Acid Derivatives	R
24: 06.08	HMG-CoA Reductase Inhibitors	R and A
24: 06.92	Niacin	R
24: 08.16	Central Alpha-agonists	R and A
24: 08.20	Direct Vasodilators	R and A
24: 12.08	Nitrates and Nitrites	R
24: 12.92	Vasodilating Agents, Miscellaneous	R

Specifications		
24: 20	Alpha-adrenergic Blocking Agents	R and A
24: 24	Beta-adrenergic Blocking Agents	R and A
24: 28.08	Dihydropyridines	R and A
24: 28.92	Calcium-Channel Blocking Agents, Miscellaneous	R and A
24: 32.04	Angiotensin-Converting Enzyme Inhibitors	R and A
24: 32.08	Angiotensin II Receptor Antagonists	R and A
28: 00	Central Nervous System Agents	
28: 08.04	Nonsteroidal Anti-inflammatory Agents except: Cyclooxygenase-2 Inhibitors	P (14 days or less)
28: 08.08	Codeine	P (12 tablets only)
28: 08.92	Acetaminophen	P
28: 12.04	Phenobarbital	R (epilepsy)
28: 12.08	Benzodiazepines (Clobazam and Clonazepam)	R (epilepsy)
28: 12.12	Hydantoins	R
28: 12.92	Anticonvulsants, Miscellaneous	R
28: 24.08	Benzodiazepines Lorazepam	R P (12 tablets only)
28: 24.92	Hydroxyzine (Chlorhydrate)	P
28: 28	Lithium	R
28: 92	Central Nervous System Agents, Miscellaneous	R
36: 00	Diagnostic Agents	

Specifications		
36: 26	Diabetes Mellitus	
	Quantitative Blood Ketone Reagent	P
	Quantitative Blood Glucose Reagent	P
36: 88	Urinalysis	P
40: 00	Electrolytic, Caloric, and Water Balance	
40: 12	Replacement Preparations	P
40: 28	Diuretics	R and A
40: 28.16	Potassium-sparing Diuretics	R
40: 36	Irrigating Solutions	P
48: 00	Respiratory Tract Agents	
48: 24	Mucolytic Agents	R
52: 00	Eye, Ear, Nose, and Throat (EENT) Preparations	
52: 02	Antiallergic Agents Sodium Cromoglicate	P
52: 04.04	Antibacterials except: Chloramphenicol Gentamicin Tobramycin	P
52: 08.08	Corticosteroids except: Ophthalmic Pomade, Solution and Suspension	P
52: 16	Local Anesthetics	P
52: 92	EENT Drugs, Miscellaneous Ipratropium (Bromide) Sodium (Chloride)	P P
56: 00	Gastrointestinal Drugs	
56: 16	Digestants Lactase	P

Specifications		
56: 22.92	Antiemetics, Miscellaneous Doxylamine/pyridoxine	P
56: 28.12	Histamine H ₂ -Antagonists Famotidine Ranitidine	R R
56: 28.28	Prostaglandins Misoprostol	R
56: 28.32	Protectants Sucralfate	P (for breastfeeding only)
56: 28.36	Proton-pump Inhibitors Esomeprazole Omeprazole Pantoprazole	R R R
56: 32	Prokinetic Agents Domperidone	R
68: 00	Hormones and Synthetic Substitutes	
68: 04	Adrenals	Aerosol only P (14 days or less)
68: 12	Contraceptives	P
68: 16.04	Estrogens	R and A
68: 16.12	Estrogen Agonists – Antagonists	R
68: 20.02	Alpha-glucosidase Inhibitors	R and A
68: 20.04	Biguanides	R and A
68: 20.08	Insulins	R and A
68: 20.20	Sulfonylureas except: Chlorpropamid	R and A
68: 22.12	Glycogenolytic Agents	R
68: 24	Parathyroid	R

Specifications		
68: 32	Progestins except: Depot Medroxyprogesterone Acetate (Depo-Provera)	R and A P
68: 36.04	Thyroid Agents except: Liothyronine Sodium	R and A
84: 00	Skin and Mucous Membrane Agents	
84: 04.04	Antibacterials	P
84: 04.08	Antifungals	P (14 days or less)
84: 04.12	Scabicides and Pediculicides	P
84: 04.92	Local anti-infective, Miscellaneous	P
84: 06	Anti-inflammatory Agents	P (medium and low strength)
84: 28	Keratolytic Agents	P
84: 32	Keratoplastic Agents	R
84: 92	Skin and Mucous Membrane Agents, Miscellaneous except: Fluorouracil	P
86: 00	Smooth Muscle Relaxants	
86: 12	Genitourinary Smooth Muscle Relaxants	R
86: 16	Respiratory Smooth Muscle Relaxants Aminophyllin Theophyllin	R R
88: 00	Vitamins	
88: 08	Vitamin B Complex except: Cyanocobalamin	P (orally only) R (including injectable)

		Specifications
88: 16	Vitamin D	P
88: 28	Multivitamin Preparations	P
92: 00	Miscellaneous Therapeutic Agents	
92: 00.02	Miscellaneous, Others	R
	Alendronate	R
	Alfuzosine	R
	Allopurinol	R
	Etidronate disodium/ calcium carbonate	R
	Finasteride	R
	Risedronate sodium	R
	Tamsulosin	R
	Terazosin	R

Local/Topical Anesthetic Agents

- Topical Lidocaine-prilocain P (stamps, pomade)
- Lidocaine Hydrochloride with or without epinephrine, injectable P (local infiltration)
P (ophthalmic solution)
- Tetracaine Hydrochloride P

Intravenous Solutions

EXCEPTION DRUGS

Generic Name	Specifications
1. Aluminum Hydroxide	P
2. Bisacodyl	P
3. Capsaicine	P
4. Donepezil	R
5. Estradiol	R and A (skin patch)
6. Galantamine	R
7. Gliclazide	R and A
8. Glimepiride	R and A
9. Mineral oil	P

Generic Name	Specifications
10. Magnesium	P
11. Memantine	R
12. Metronidazole	P
13. Island dressings	P
14. Alginate dressings	P
15. Activated charcoal dressing	P
16. Sodium chloride dressing	P
17. Hydrocolloid dressing	P
18. Hydrofiber dressing	P
19. Iodized dressings	P
20. Hydrophilic foam dressings	P
21. Multilayer dressing	P
22. Monobasic sodium phosphate/Dibasic sodium phosphate	P
23. Pioglitazone	R and A
24. Micronized progesterone	R
25. Coaguchek PTS	P
26. Repaglinide	R and A
27. Rivastigmine	R
28. Rosiglitazone	R and A
29. Salmeterol/Fluticasone	R
30. Senosides A and B	P
31. Tolterodine	R
32. Tretinoine	P

9. This Regulation comes into force on the fifteenth day after the date of its publication in the *Gazette officielle du Québec*.